期刊文献+

Pathological consequences of C-peptide deficiency in insulin-dependent diabetes mellitus 被引量:6

Pathological consequences of C-peptide deficiency in insulin-dependent diabetes mellitus
下载PDF
导出
摘要 Diabetes is associated with several complications such as retinopathy, nephropathy, neuropathy and cardiovascular diseases. Currently, insulin is the main used medication for management of insulin-dependentdiabetes mellitus(type-1 diabetes). In this metabolic syndrome, in addition to decrease of endogenous insulin, the plasma level of connecting peptide(C-peptide) is also reduced due to beta cell destruction. Studies in the past decade have shown that C-peptide is much more than a byproduct of insulin biosynthesis and possess different biological activities. Therefore, it may be possible that C-peptide deficiency be involved, at least in part, in the development of different complications of diabetes. It has been shown that a small level of remaining C-peptide is associated with significant metabolic benefit. The purpose of this review is to describe beneficial effects of C-peptide replacement on pathological features associated with insulin-dependent diabetes. Also, experimental and clinical findings on the effects of C-peptide on wholebody glucose utilization, adipose tissue metabolism and tissues blood flow are summarized and discussed. The hypoglycemic, antilipolytic and vasodilator effects of C-peptide suggest that it may contribute to fine-tuning of the tissues metabolism under different physiologic or pathologic conditions. Therefore, C-peptide replacement together with the classic insulin therapy may prevent, retard, or ameliorate diabetic complications in patients with type-1 diabetes. Diabetes is associated with several complicationssuch as retinopathy, nephropathy, neuropathy andcardiovascular diseases. Currently, insulin is the mainused medication for management of insulin-dependentdiabetes mellitus (type-1 diabetes). In this metabolicsyndrome, in addition to decrease of endogenous insulin,the plasma level of connecting peptide (C-peptide) is alsoreduced due to beta cell destruction. Studies in the pastdecade have shown that C-peptide is much more than abyproduct of insulin biosynthesis and possess differentbiological activities. Therefore, it may be possible thatC-peptide deficiency be involved, at least in part, in thedevelopment of different complications of diabetes. It hasbeen shown that a small level of remaining C-peptide isassociated with significant metabolic benefit. The purposeof this review is to describe beneficial effects of C-peptidereplacement on pathological features associated withinsulin-dependent diabetes. Also, experimental andclinical findings on the effects of C-peptide on wholebodyglucose utilization, adipose tissue metabolism andtissues blood flow are summarized and discussed. Thehypoglycemic, antilipolytic and vasodilator effects ofC-peptide suggest that it may contribute to fine-tuningof the tissues metabolism under different physiologic orpathologic conditions. Therefore, C-peptide replacementtogether with the classic insulin therapy may prevent,retard, or ameliorate diabetic complications in patientswith type-1 diabetes.
出处 《World Journal of Diabetes》 SCIE CAS 2015年第1期145-150,共6页 世界糖尿病杂志(英文版)(电子版)
基金 Supported by Mashhad University of Medical Sciences
关键词 C-PEPTIDE DIABETES INSULIN NEPHROPATHY NEUROPATHY C-peptide Diabetes Insulin Nephropathy Neuropathy
  • 相关文献

参考文献60

  • 1Deshpande AD, Harris-Hayes M, Schootman M. Epidemiologyof diabetes and diabetes-related complications. PhysTher 2008; 88: 1254-1264 [PMID: 18801858 DOI: 10.2522/ptj.20080020].
  • 2Aathira R, Jain V. Advances in management of type 1diabetes mellitus. World J Diabetes 2014; 5: 689-696 [PMID:25317246 DOI: 10.4239/wjd.v5.i5.689].
  • 3Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P.Risk of cardiovascular disease and all cause mortality amongpatients with type 2 diabetes prescribed oral antidiabetesdrugs: retrospective cohort study using UK general practiceresearch database. BMJ 2009; 339: b4731 [DOI: 10.1136/bmj.b4731].
  • 4Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, JansaLD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS,Steffes MW. C-peptide is the appropriate outcome measurefor type 1 diabetes clinical trials to preserve beta-cellfunction: report of an ADA workshop, 21-22 October 2001.Diabetes 2004; 53: 250-264 [PMID: 14693724 DOI: 10.2337/diabetes.53.1.250].
  • 5Eisenbarth GS, Buse JB. Type 1 diabetes mellitus. In:Melmed S, Polonsky KS, Larsen PR. Williams textbook ofendocrinology. Philadelphia: Elsevier, 2011: 1436-1453.
  • 6Marques RG, Fontaine MJ, Rogers J. C-peptide: much morethan a byproduct of insulin biosynthesis. Pancreas 2004; 29:231-238 [PMID: 15367890 DOI: 10.1097/00006676-200410000-00009].
  • 7Steiner DF, Bell GI, Rubenstein AH. Chemistry andbiosynthesis of the islet hormones. In: DeGroot L, JamesonJL. Endocrinology. Philadelphia: Elsevier, 2006: 925-960.
  • 8Habener JF. Genetic control of peptide hormone formation.In: Melmed S, Polonsky KS, Larsen PR. Williams textbook ofendocrinology. Philadelphia: Elsevier, 2011: 31-43.
  • 9Li L, Oshida Y, Kusunoki M, Yamanouchi K, Johansson BL,Wahren J, Sato Y. Rat C peptide I and II stimulate glucoseutilization in STZ-induced diabetic rats. Diabetologia 1999; 42:958-964 [PMID: 10491756 DOI: 10.1007/s001250051254].
  • 10Kuzuya H, Blix PM, Horwitz DL, Rubenstein AH, SteinerDF, Faber OK, Binder C. Heterogeneity of circulating humanC-peptide. Diabetes 1978; 27 Suppl 1: 184-191 [PMID: 75814DOI: 10.2337/diab.27.1.S184].

同被引文献41

  • 1褚佩英.老年人空腹胰岛素、C肽水平分析[J].临床检验杂志(电子版),2013,2(1):278-280. 被引量:1
  • 2洪世华,肖常青.C肽与糖尿病并发症关系的研究进展[J].内科,2006,1(2):152-153. 被引量:4
  • 3汪向东,王希林,马弘,等.心理卫生评定量表手册[M].北京:中国心理卫生杂志社,1999.
  • 4郝伟,于欣.精神病学[M].北京:人民卫生出版社,2013:192-193.
  • 5Hasan S S,Clavarino A M,Mamun A A,et al.Anxiety symptoms and the risk of diabetes mellitus in Australian women:Evidence from 21-year follow-up[J].Public Health,2016,130:21-28.
  • 6Abraham S,Shah N G,Roux A D,et al.Trait anger but not anxiety predicts incident type 2diabetes:The multi-ethnic study of atherosclerosis(MESA)[J].Psychoneuroendocrinology,2015,60:105-113.
  • 7Nefs G,Donga E,van Someren E,et al.Subjective sleep impairment in adults with type 1or type 2diabetes:Results from Diabetes MILES-The Netherlands[J].Diabetes Research and Clinical Practice,2015,109(3):466-475.
  • 8Erden S,Kaya H.Sexual dysfunction and anxiety levels of type 2male diabetics[J].Applied Nursing Research,2015,28(3):239-243.
  • 9Raffield L M,Brenes G A,Cox A J,et al.Associations between anxiety and depression symptoms and cognitive testing and neuroimaging in type 2diabetes[J].Journal of Diabetes and Its Complications,2016,30(1):143-149.
  • 10Oukic I,Mottus R,Luciano M,et al.Do personality traits moderate the manifestation of type 2diabetes genetic risk?[J].Journal of Psychosomatic Research,2015,79(4):303-308.

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部